Latest Alexza Pharmaceuticals (ALXA) Headlines
Post# of 12
Posted On: 03/12/2014 5:43:30 PM
Latest Alexza Pharmaceuticals (ALXA) Headlines
Alexza Reports Fourth Quarter and Year End 2013 Financial Results
PR Newswire - Thu Mar 06, 3:05PM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter and year ended December 31, 2013. The net loss for the fourth quarter was $5.7 million compared to $10.3 million during the same quarter in 2012. The net loss for the years ended December 31, 2013 and 2012 was $39.6 million and $28.0 million, respectively. At December 31, 2013, Alexza had consolidated cash, cash equivalents and marketable securities of $25.9 million.
Teva Launches ADASUVE(R) in U.S.
Business Wire - Mon Mar 03, 7:15AM CST
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today the commercial launch of ADASUVE(R) (loxapine) inhalation powder 10 mg, the first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.
Alexza Announces the U.S. Commercial Launch of ADASUVE® by Teva Pharmaceuticals
PR Newswire - Mon Mar 03, 7:07AM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced the U.S. commercial launch of ADASUVE® (loxapine) inhalation powder 10mg by its commercial partner, Teva Pharmaceutical Industries Ltd., (NYSE: TEVA). ADASUVE is the first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.
Robert A. Lippe Joins Alexza Pharmaceuticals as Executive Vice President, Operations and Chief Operations Officer
PR Newswire - Tue Feb 25, 8:00AM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that Robert A. Lippe has joined the Company as Executive Vice President, Operations and Chief Operations Officer. In this newly created position, Mr. Lippe has responsibility for the Company's global operation functions, including strategic development and execution of clinical and commercial manufacturing, quality and compliance, supply chain and supply partner management, technology transfer, facilities, sustainment engineering and IT in support of the Company's product and technology portfolio.
Alexza Pharmaceuticals' Corporate Presentation to be Webcast from Two Upcoming March Investor Conferences
PR Newswire - Thu Feb 20, 4:00PM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today its corporate presentation will be webcast live from two upcoming investor conferences. The webcast of each presentation may be accessed from the Investor Relations section of the Alexza Pharmaceuticals website at www.alexza.com. The conferences and presentation times are:
Alexza to Report 2013 Year-End Financial Results on Thursday, March 6, 2014
PR Newswire - Thu Feb 13, 8:00AM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) will report results for its fiscal year ended December 31, 2013 on Thursday, March 6, 2014, following the close of the U.S. financial markets. The Company will also host an investor conference call and live webcast on the same day at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time to provide a company update and discuss the financial results.
Alexza Pharmaceuticals Inc reports availability of ADASUVE in Spain through Grupo Ferrer Internacional SA
M2 - Wed Jan 22, 4:27AM CST
Pharmaceutical company Alexza Pharmaceuticals Inc (NasdaqGM:ALXA) reported on Tuesday the launch of ADASUVE inhalation powder, pre-dispensed in Spain through Grupo Ferrer Internacional SA.
Alexza Pharmaceuticals Announces Ferrer's Launch of ADASUVE® (Staccato® Loxapine) in Spain Triggering a $1 Million Milestone Payment
PR Newswire - Tue Jan 21, 8:05AM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced that ADASUVE® inhalation powder, pre-dispensed (Staccato® loxapine) is now available in Spain through Grupo Ferrer Internacional, S.A. (Ferrer). Ferrer is Alexza's commercial partner for ADASUVE in the European Union (EU), Latin America, Russia and the CIS countries. In conjunction with this commercial introduction of ADASUVE in Spain by Ferrer, Alexza will receive a milestone payment of $1 million.
Alexza Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
PR Newswire - Thu Nov 21, 3:15PM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that the Company will participate in the 25th Annual Piper Jaffray Healthcare Conference, being held in New York, NY, on December 3 - 4, 2013. Thomas B. King, Alexza President and CEO, will present at the conference. The Alexza corporate presentation will be Tuesday, December 3, 2013 at 2:30 p.m. Eastern Time. The presentation will be webcast live.
Alexza Reports 2013 Third Quarter Financial Results
PR Newswire - Wed Nov 06, 3:05PM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter ended September 30, 2013. The net loss for the third quarter was $12.4 million compared to $6.9 million during the same quarter in 2012. The net loss for the nine months ended September 30, 2013 and 2012, was $33.9 million and $17.7 million, respectively. At September 30, 2013, Alexza had consolidated cash, cash equivalents and marketable securities of $32.5 million.
Alexza Pharmaceuticals and Grupo Ferrer Announce the Launch of ADASUVE® (Staccato® Loxapine) in Austria
PR Newswire - Thu Oct 24, 8:00AM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) and Grupo Ferrer Internacional, S.A. (Ferrer) today announced that ADASUVE® inhalation powder, pre-dispensed (Staccato® loxapine) is now available in Austria. Ferrer is Alexza's commercial partner for ADASUVE in the European Union (EU), Latin America, Russia and the CIS countries. Ferrer is commercializing ADASUVE in Austria through a distribution agreement with AOP Orphan Pharmaceuticals AG, headquartered in Vienna, Austria.
Global Migraine Clinical Trials Review Report, H2 2013
M2 - Fri Oct 18, 6:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dq5635/migraine_global) has announced the addition of the "Migraine Global Clinical Trials Review, H2, 2013" report to their offering. Migraine Global Clinical Trials Review, H2, 2013 provides data on the Migraine clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Migraine. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Migraine. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Migraine Therapeutics Clinical Trials - Alexza Pharmaceuticals, Inc. - Allergan, Inc. - AstraZeneca PLC - Banyan Group, Inc. - Endo Health Solutions Inc. - GlaxoSmithKline plc - Johnson & Johnson - Merck & Co., Inc. - NuPathe Inc. - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/dq...ine_global
Alexza to Report 2013 Third Quarter Financial Results on Wednesday, November 6, 2013
PR Newswire - Wed Oct 16, 3:15PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) will report results for its fiscal quarter ended September 30, 2013 on Wednesday, November 6, 2013, following the close of the U.S. financial markets. The Company will also host an investor conference call and live webcast on the same day at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time to provide a company update and discuss the financial results.
Alexza Pharmaceuticals to Present at the Stifel Healthcare Conference 2013
PR Newswire - Thu Aug 29, 3:15PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that the Company will participate in the Stifel Healthcare Conference 2013, being held in Boston, MA, September 11 - 12, 2013. James V. Cassella, PhD, Alexza Executive Vice President and Chief Scientific Officer, will present at the conference. The Alexza corporate presentation will be Wednesday, September 11, 2013 at 9:10 a.m. Eastern Time. The presentation will be webcast live.
Edison expands North American healthcare sector coverage with initiation of coverage on Alexza Pharmaceuticals
PR Newswire - Wed Aug 28, 10:18AM CDT
Edison has recently published a comprehensive report examining the investment merits of Alexza Pharmaceuticals, which are largely based on the company's lead asset, Adasuve (Staccato loxapine), approved in the US and the EU for the acute treatment of agitation in adults with bipolar disorder or schizophrenia. In the report, All eyes on Adasuve, Edison healthcare analyst, Pooya Hemami, argues that Alexza's investment case is underpinned by Adasuve's ability to provide a rapid therapeutic response in a non-invasive formulation, offering a unique treatment option that does not require physicians to trade off either speed of effect or non-coercive dosing. Given the risk of physical injury or property damage with agitated patients in whom agitation is escalating, and that competing treatment options are either slow to act or invasive, Edison believes the advantages of quick effect and ease of administration will position Adasuve as a key agent for the initial treatment of acute agitation in medical emergency settings. Based on a risk-adjusted NPV analysis, Edison values Alexza at $85m, or $6.77 per share (fully diluted) inclusive of $32m in cash (30 June 2013).
Alexza Pharmaceuticals Down 7.5%, Shares Slide into the Red (ALXA)
Comtex SmarTrend(R) - Fri Aug 09, 10:16AM CDT
Alexza Pharmaceuticals (NASDAQ:ALXA) is one of today's worst performing low-priced stocks, down 7.5% to $4.81 on 1.6x average daily volume. Thus far today, Alexza Pharmaceuticals has traded 378,000 shares, vs. average volume of 241,000 shares per day. The stock has underperformed the Dow (-7.5% to the Dow's -0.7%) and underperformed the S&P 500 (-7.5% to the S&P's -0.4%) during today's trading.
Alexza Reports Preliminary 2013 Second Quarter Financial Results
PR Newswire - Thu Aug 08, 3:05PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported preliminary financial results for the quarter ended June 30, 2013. The preliminary net loss for the quarter ended June 30, 2013, was $3.4 million compared to $7.0 million during the same quarter in 2012. The preliminary net loss for the six months ended June 30, 2013 and 2012, was $24.1 million and $10.8 million, respectively. At June 30, 2013, Alexza had consolidated cash, cash equivalents and marketable securities of $35.0 million.
Alexza Pharmaceuticals to Present at the 2013 Wedbush Life Sciences Management Access Conference
PR Newswire - Tue Aug 06, 3:15PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that the Company will participate in the 2013 Wedbush Life Sciences Management Access Conference, being held in New York, New York, August 13 - 14, 2013. Thomas B. King, Alexza President and CEO, will present at the conference. The Alexza corporate presentation will be Wednesday, August 14, 2013 at 8:35 a.m. Eastern Time. The presentation will be webcast live.
Alexza Announces Management Promotions
PR Newswire - Thu Aug 01, 8:00AM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced the promotion of Kelly Seither to the newly created position of Vice President, Global Strategic Marketing and New Product Planning, and Tatjana Naranda, PhD, to the newly created position of Vice President, Business Development and Global Alliance Management.
Alexza Pharmaceuticals Inc reports availibility of ADASUVE (Staccato Loxapine) in the EU, with first product sales in Germany
M2 - Wed Jul 31, 10:29AM CDT
Alexza Pharmaceuticals Inc (ALXA) said on Tuesday that its commercial partner Grupo Ferrer Internacional SA has initiated sales of ADASUVE inhalation powder, pre-dispensed (Staccato Loxapine) in the EU.
Alexza Reports Fourth Quarter and Year End 2013 Financial Results
PR Newswire - Thu Mar 06, 3:05PM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter and year ended December 31, 2013. The net loss for the fourth quarter was $5.7 million compared to $10.3 million during the same quarter in 2012. The net loss for the years ended December 31, 2013 and 2012 was $39.6 million and $28.0 million, respectively. At December 31, 2013, Alexza had consolidated cash, cash equivalents and marketable securities of $25.9 million.
Teva Launches ADASUVE(R) in U.S.
Business Wire - Mon Mar 03, 7:15AM CST
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today the commercial launch of ADASUVE(R) (loxapine) inhalation powder 10 mg, the first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.
Alexza Announces the U.S. Commercial Launch of ADASUVE® by Teva Pharmaceuticals
PR Newswire - Mon Mar 03, 7:07AM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced the U.S. commercial launch of ADASUVE® (loxapine) inhalation powder 10mg by its commercial partner, Teva Pharmaceutical Industries Ltd., (NYSE: TEVA). ADASUVE is the first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.
Robert A. Lippe Joins Alexza Pharmaceuticals as Executive Vice President, Operations and Chief Operations Officer
PR Newswire - Tue Feb 25, 8:00AM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that Robert A. Lippe has joined the Company as Executive Vice President, Operations and Chief Operations Officer. In this newly created position, Mr. Lippe has responsibility for the Company's global operation functions, including strategic development and execution of clinical and commercial manufacturing, quality and compliance, supply chain and supply partner management, technology transfer, facilities, sustainment engineering and IT in support of the Company's product and technology portfolio.
Alexza Pharmaceuticals' Corporate Presentation to be Webcast from Two Upcoming March Investor Conferences
PR Newswire - Thu Feb 20, 4:00PM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today its corporate presentation will be webcast live from two upcoming investor conferences. The webcast of each presentation may be accessed from the Investor Relations section of the Alexza Pharmaceuticals website at www.alexza.com. The conferences and presentation times are:
Alexza to Report 2013 Year-End Financial Results on Thursday, March 6, 2014
PR Newswire - Thu Feb 13, 8:00AM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) will report results for its fiscal year ended December 31, 2013 on Thursday, March 6, 2014, following the close of the U.S. financial markets. The Company will also host an investor conference call and live webcast on the same day at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time to provide a company update and discuss the financial results.
Alexza Pharmaceuticals Inc reports availability of ADASUVE in Spain through Grupo Ferrer Internacional SA
M2 - Wed Jan 22, 4:27AM CST
Pharmaceutical company Alexza Pharmaceuticals Inc (NasdaqGM:ALXA) reported on Tuesday the launch of ADASUVE inhalation powder, pre-dispensed in Spain through Grupo Ferrer Internacional SA.
Alexza Pharmaceuticals Announces Ferrer's Launch of ADASUVE® (Staccato® Loxapine) in Spain Triggering a $1 Million Milestone Payment
PR Newswire - Tue Jan 21, 8:05AM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced that ADASUVE® inhalation powder, pre-dispensed (Staccato® loxapine) is now available in Spain through Grupo Ferrer Internacional, S.A. (Ferrer). Ferrer is Alexza's commercial partner for ADASUVE in the European Union (EU), Latin America, Russia and the CIS countries. In conjunction with this commercial introduction of ADASUVE in Spain by Ferrer, Alexza will receive a milestone payment of $1 million.
Alexza Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
PR Newswire - Thu Nov 21, 3:15PM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that the Company will participate in the 25th Annual Piper Jaffray Healthcare Conference, being held in New York, NY, on December 3 - 4, 2013. Thomas B. King, Alexza President and CEO, will present at the conference. The Alexza corporate presentation will be Tuesday, December 3, 2013 at 2:30 p.m. Eastern Time. The presentation will be webcast live.
Alexza Reports 2013 Third Quarter Financial Results
PR Newswire - Wed Nov 06, 3:05PM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter ended September 30, 2013. The net loss for the third quarter was $12.4 million compared to $6.9 million during the same quarter in 2012. The net loss for the nine months ended September 30, 2013 and 2012, was $33.9 million and $17.7 million, respectively. At September 30, 2013, Alexza had consolidated cash, cash equivalents and marketable securities of $32.5 million.
Alexza Pharmaceuticals and Grupo Ferrer Announce the Launch of ADASUVE® (Staccato® Loxapine) in Austria
PR Newswire - Thu Oct 24, 8:00AM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) and Grupo Ferrer Internacional, S.A. (Ferrer) today announced that ADASUVE® inhalation powder, pre-dispensed (Staccato® loxapine) is now available in Austria. Ferrer is Alexza's commercial partner for ADASUVE in the European Union (EU), Latin America, Russia and the CIS countries. Ferrer is commercializing ADASUVE in Austria through a distribution agreement with AOP Orphan Pharmaceuticals AG, headquartered in Vienna, Austria.
Global Migraine Clinical Trials Review Report, H2 2013
M2 - Fri Oct 18, 6:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dq5635/migraine_global) has announced the addition of the "Migraine Global Clinical Trials Review, H2, 2013" report to their offering. Migraine Global Clinical Trials Review, H2, 2013 provides data on the Migraine clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Migraine. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Migraine. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Migraine Therapeutics Clinical Trials - Alexza Pharmaceuticals, Inc. - Allergan, Inc. - AstraZeneca PLC - Banyan Group, Inc. - Endo Health Solutions Inc. - GlaxoSmithKline plc - Johnson & Johnson - Merck & Co., Inc. - NuPathe Inc. - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/dq...ine_global
Alexza to Report 2013 Third Quarter Financial Results on Wednesday, November 6, 2013
PR Newswire - Wed Oct 16, 3:15PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) will report results for its fiscal quarter ended September 30, 2013 on Wednesday, November 6, 2013, following the close of the U.S. financial markets. The Company will also host an investor conference call and live webcast on the same day at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time to provide a company update and discuss the financial results.
Alexza Pharmaceuticals to Present at the Stifel Healthcare Conference 2013
PR Newswire - Thu Aug 29, 3:15PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that the Company will participate in the Stifel Healthcare Conference 2013, being held in Boston, MA, September 11 - 12, 2013. James V. Cassella, PhD, Alexza Executive Vice President and Chief Scientific Officer, will present at the conference. The Alexza corporate presentation will be Wednesday, September 11, 2013 at 9:10 a.m. Eastern Time. The presentation will be webcast live.
Edison expands North American healthcare sector coverage with initiation of coverage on Alexza Pharmaceuticals
PR Newswire - Wed Aug 28, 10:18AM CDT
Edison has recently published a comprehensive report examining the investment merits of Alexza Pharmaceuticals, which are largely based on the company's lead asset, Adasuve (Staccato loxapine), approved in the US and the EU for the acute treatment of agitation in adults with bipolar disorder or schizophrenia. In the report, All eyes on Adasuve, Edison healthcare analyst, Pooya Hemami, argues that Alexza's investment case is underpinned by Adasuve's ability to provide a rapid therapeutic response in a non-invasive formulation, offering a unique treatment option that does not require physicians to trade off either speed of effect or non-coercive dosing. Given the risk of physical injury or property damage with agitated patients in whom agitation is escalating, and that competing treatment options are either slow to act or invasive, Edison believes the advantages of quick effect and ease of administration will position Adasuve as a key agent for the initial treatment of acute agitation in medical emergency settings. Based on a risk-adjusted NPV analysis, Edison values Alexza at $85m, or $6.77 per share (fully diluted) inclusive of $32m in cash (30 June 2013).
Alexza Pharmaceuticals Down 7.5%, Shares Slide into the Red (ALXA)
Comtex SmarTrend(R) - Fri Aug 09, 10:16AM CDT
Alexza Pharmaceuticals (NASDAQ:ALXA) is one of today's worst performing low-priced stocks, down 7.5% to $4.81 on 1.6x average daily volume. Thus far today, Alexza Pharmaceuticals has traded 378,000 shares, vs. average volume of 241,000 shares per day. The stock has underperformed the Dow (-7.5% to the Dow's -0.7%) and underperformed the S&P 500 (-7.5% to the S&P's -0.4%) during today's trading.
Alexza Reports Preliminary 2013 Second Quarter Financial Results
PR Newswire - Thu Aug 08, 3:05PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported preliminary financial results for the quarter ended June 30, 2013. The preliminary net loss for the quarter ended June 30, 2013, was $3.4 million compared to $7.0 million during the same quarter in 2012. The preliminary net loss for the six months ended June 30, 2013 and 2012, was $24.1 million and $10.8 million, respectively. At June 30, 2013, Alexza had consolidated cash, cash equivalents and marketable securities of $35.0 million.
Alexza Pharmaceuticals to Present at the 2013 Wedbush Life Sciences Management Access Conference
PR Newswire - Tue Aug 06, 3:15PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that the Company will participate in the 2013 Wedbush Life Sciences Management Access Conference, being held in New York, New York, August 13 - 14, 2013. Thomas B. King, Alexza President and CEO, will present at the conference. The Alexza corporate presentation will be Wednesday, August 14, 2013 at 8:35 a.m. Eastern Time. The presentation will be webcast live.
Alexza Announces Management Promotions
PR Newswire - Thu Aug 01, 8:00AM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced the promotion of Kelly Seither to the newly created position of Vice President, Global Strategic Marketing and New Product Planning, and Tatjana Naranda, PhD, to the newly created position of Vice President, Business Development and Global Alliance Management.
Alexza Pharmaceuticals Inc reports availibility of ADASUVE (Staccato Loxapine) in the EU, with first product sales in Germany
M2 - Wed Jul 31, 10:29AM CDT
Alexza Pharmaceuticals Inc (ALXA) said on Tuesday that its commercial partner Grupo Ferrer Internacional SA has initiated sales of ADASUVE inhalation powder, pre-dispensed (Staccato Loxapine) in the EU.
(0)
(0)Alexza Pharmaceuticals (ALXA) Stock Research Links
Scroll down for more posts ▼